Ditiocarb  (Synonyms: Diethyldithiocarbamic acid)

Ditiocarb (Diethyldithiocarbamic acid) is an accelerator of the rate of copper cementation. Ditiocarb (Diethyldithiocarbamic acid) reduces the incidence of HIV infection, and also enhances adjuvant immunotherapy of high risk breast cancer^[1][2][3].

Ditiocarb reacts with the Cu²⁺ solution giving a complex of copper diethyldithiocarbamate, which enhances the rate of cementation^[1]. Ditiocarb is an agent with strong antioxidant capacity and chelating activities^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Ditiocarb improves the depressed immune responses of newborn and aged mice. Ditiocarb prevents cisplatin nephrotoxicity in animals without reducing the antitumor activity.
In that AIDS model, Ditiocarb reduces lymphadenopathy and hypergammaglobulinemia, restores immunocompetence, and prolongs survival^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

149.28

C₅H₁₁NS₂

147-84-2

SC(N(CC)CC)=S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Abeer A.El-Saharty, et al. Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation. The Egyptian Journal of Aquatic Research. 2015 Dec, Volume 41(4):289-293.

  [2]. Hersh EM, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265(12):1538-44.  [Content Brief]

  [3]. Dufour P, et al. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy. 1993;6(1):9-12.  [Content Brief]